CRM
Salesforce, Inc.
CRM has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has a slight edge over CRM overall, supported by stronger fundamentals and stronger modeled upside.
CRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
CRM's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $218 | — |
| Cheap | 36x | $393 | +80% |
| Fair | 70x | $766 | +252% |
| Expensive | 293x | $3,206 | +1374% |
Historical ranges are pointers, not guarantees.
CRM's PE is in its cheap range at 20x, but its recent earnings include one-off gains.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CRM in the historical PE scenario, which offers more potential upside but is not a forecast.
CRM Forward outlook
There aren't enough analyst estimates for CRM to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $10.96 | +59% |
| Q2 2026 | $8.63 | +35% |
| Q1 2026 | $7.80 | +23% |
| Q4 2025 | $7.49 | +23% |
| Q3 2025 | $6.88 | +20% |
| Q2 2025 | $6.39 | +15% |
| Q1 2025 | $6.36 | +51% |
| Q4 2024 | $6.08 | +131% |
CRM has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
CRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3B | +11% |
| Q2 2026 | $11.1B | +13% |
| Q1 2026 | $11.2B | +12% |
| Q4 2025 | $10.3B | +8.6% |
| Q3 2025 | $10.2B | +9.8% |
| Q2 2025 | $9.8B | +7.6% |
| Q1 2025 | $10B | +7.6% |
| Q4 2024 | $9.4B | +8.3% |
CRM's revenue has grown year over year every quarter since late 2020: $11.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -2.2 points |
| Q2 2026 | 21% | +1.3 points |
| Q1 2026 | 17% | -1.5 points |
| Q4 2025 | 21% | +1.3 points |
| Q3 2025 | 23% | +3.7 points |
| Q2 2025 | 20% | +1.1 points |
| Q1 2025 | 18% | +0.7 points |
| Q4 2024 | 20% | +2.8 points |
CRM has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +81% |
| Q2 2026 | $6.6B | +4.1% |
| Q1 2026 | $5.3B | +39% |
| Q4 2025 | $2.2B | +22% |
| Q3 2025 | $605M | -20% |
| Q2 2025 | $6.3B | +3.5% |
| Q1 2025 | $3.8B | +17% |
| Q4 2024 | $1.8B | +30% |
CRM has the edge over OSCR on cash flow, with more consistent year-over-year improvement.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
CRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.7% | -50M shares |
| 1 year | -15% | -141M shares |
| 3 years | -17% | -165M shares |
| 5 years | -14% | -129M shares |
| Available history | -6.6% | -58M shares |
CRM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $84M |
| Q2 2026 | $27.2B |
| Q1 2026 | $3.9B |
| Q4 2025 | $3.8B |
| Q3 2025 | $2.2B |
| Q2 2025 | $2.6B |
| Q1 2025 | $76M |
| Q4 2024 | $1.3B |
CRM spent $35.1B buying back its own shares over the past year, about six times what it spent the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 0.0x | Very low |
CRM's net debt is about 2.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CRM on leverage, with a lower net debt burden relative to earnings.
CRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 44.2 | Neutral |
CRM's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRM PE vs Technology Sector
| Metric | CRM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 29% below |
| PE % | 2 | 35 | 33 pts below |
CRM is trading at 20x earnings, a 29% discount to the Technology sector's median of 28x, though its recent earnings include one-off gains.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CRM on valuation relative to its sector.
CRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $230.9 | 5.8% below |
| 20 week MA | $214.7 | 1.3% above |
| 50 week MA | $206.8 | 5.2% above |
| 100 week MA | $239.7 | 9.2% below |
| 200 week MA | $242.0 | 10% below |
CRM's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CRM on trend strength, trading above more of its moving averages.
CRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $165.0 | $225.8 | +37% |
| 2021 | $225.8 | $253.1 | +12% |
| 2022 | $253.1 | $129.4 | -49% |
| 2023 | $129.4 | $263.1 | +103% |
| 2024 | $263.1 | $338.5 | +29% |
| 2025 | $338.5 | $266.1 | -21% |
| 2026 YTD | $266.1 | $217.6 | -18% |
CRM's yearly returns have swung widely, from +103% in 2023 to −49% in 2022. It's down 18% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRM on returns for 2026, with the stronger performance.